Clinical evidence dossier
Dipeptidyl peptidase-4 inhibitors
HbA1c
Evidence signal
Authoritative evidence signal
strong
This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.
Evidence snapshot
- Authoritative support records
- 5
- Supporting studies available for review
- 5
- Randomized trials
- 5
- Reported effects
- 12
Clinical conclusion
Dipeptidyl peptidase-4 inhibitors shows a strong positive evidence signal for improving HbA1c across the studied comparisons.
Observed effects
Observed study estimates; not a pooled treatment effect.
Change from baseline
Absolute change
-1.74 to -1.74 %
Change from baseline
Mean difference
-1.35 to 0 %
Evidence composition
- Non-randomized studies
- 0
- Other designs
- 0
- Unresolved designs
- 0
- Magnitude-eligible effects
- 10
Consistency
Authoritative consistency classification
consistent
- Positive
- 5
- No effect
- 0
- Mixed
- 0
- Negative
- 0
Population and applicability
Structured population data were available for 5 of 5 supporting studies. 5 studies described participants with type 2 diabetes. 4 studies described adult participants.
This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.
View reported population descriptions
These descriptions are reported across the supporting studies; they are not a single synthesized population.
- Adolescents and young adults aged 10-25 with Type 2 diabetes.
- Patients seeking alternative diabetes treatments.
- Adults with uncontrolled type 2 diabetes.
- Patients not achieving glycemic targets with current diabetes medications.
- Adults with inadequately controlled Type 2 Diabetes.
- Patients seeking additional treatment options for glycemic control.
- Adults newly diagnosed with Type 2 diabetes.
- Patients seeking pharmacological management for diabetes.
- Adults newly diagnosed with Type 2 Diabetes
- Patients requiring pharmacological intervention for diabetes management
Limitations
- Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, placebo.
Supporting evidence
Inspect the authoritative studies and omitted support records for this dossier.